Research & Development

Will Aktis Oncology Lead the Radiopharma Cancer Treatment Revolution?
Research & Development Will Aktis Oncology Lead the Radiopharma Cancer Treatment Revolution?

Boston-based Aktis Oncology is making significant strides in the biopharmaceutical industry, standing out for its innovative efforts in developing radiopharmaceutical medicines aimed at treating cancer. The company recently secured a substantial $175 million in a Series B funding round, designed to

Which Top Biopharma Conferences Should You Attend in 2025?
Research & Development Which Top Biopharma Conferences Should You Attend in 2025?

The biotech and pharmaceutical industries are highly dynamic fields reliant on constant innovation, robust networking, and strategic investor relations. Professionals in these sectors must attend top biopharma conferences to keep pace with the latest advancements, regulatory trends, and emerging

Seelos, U.S. Army Partner on SLS-002 for Breakthrough PTSD Treatment
Research & Development Seelos, U.S. Army Partner on SLS-002 for Breakthrough PTSD Treatment

Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, has reached a significant milestone in the development of treatments for post-traumatic stress disorder (PTSD). The company recently announced a Material Transfer Agreement (MTA) with the U.S. Army Medical

BioAge's $198M IPO Marks Major Shift Towards Innovative Obesity Drugs
Research & Development BioAge's $198M IPO Marks Major Shift Towards Innovative Obesity Drugs

BioAge Labs has recently garnered significant attention with its successful initial public offering (IPO), raising a formidable $198 million. Demonstrating the company's strategic pivot towards obesity drug research, this financial feat is particularly notable given the challenging environment for

How Will Lonza-Vertex Deal Transform Gene Therapy for SCD and Thalassemia?
Research & Development How Will Lonza-Vertex Deal Transform Gene Therapy for SCD and Thalassemia?

The long-term commercial supply agreement between Lonza and Vertex Pharmaceuticals marks a pivotal moment in the field of gene therapy, promising significant advancements for patients suffering from sickle cell disease (SCD) and beta-thalassemia. This collaboration focuses on the production of

Engaging Biopharma and Government to Combat Resurgent Mpox
Research & Development Engaging Biopharma and Government to Combat Resurgent Mpox

Mpox has made a concerning comeback, compelling immediate and collaborative action. With an increased threat from the Clade Ib strain, the situation demands an effective response framework modeled after successful strategies used in the COVID-19 pandemic. This involves substantial input from both

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later